The drug is a shim until gene therapy is proven safe and effective. We are patching a bug in the human wrt the peptide hormone mechanism in scope. It is, very broadly speaking, a reward center defect. Morally speaking, we should show the human grace and attempt to assist humans with this buggy reward center at scale via bioengineering.
Declaring broad swaths of people "defective" because they don't subscribe to the same value is you seems quite dystopian to me. You say messiah, I say Nazi.
Having a medical condition isn't a moral failing; observing said medical conditions and advocating for providing help with potentially malfunctioning reward centers leading to lower agency and desired individual outcome doesn't strike me as "being a Nazi.". If a human doesn't want the help, they don't have to take it. If they do, make it widely and affordably available. Strange take. Context below.
> The consistency that I'm hearing from all across patient groups is gain of control, whereas previously, there was a loss of control… All of a sudden they're able to step back and say, 'oh, well I had this shopping phenomenon that was going on, gambling, addiction, or alcoholism, and all of a sudden, it just stopped,' -- Dr. Gitanjali Srivastava, Vanderbilt Medical Center
> 1. GLP-1 drugs appear to dramatically reduce addictive drive across substances. 2. GLP-1 drugs can reach vastly more patients than existing medications and they have positive mental health benefits for anxiety and depression. 3. This is our first ever opportunity to make a big dent in the addiction crisis, which kills 770,000 people a year between opioids, cigarettes, and alcohol.
https://www.fractyl.com/fractyl-health-demonstrates-signific...